Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news


From To
South Africa death rates declined due to HIV success – report

Death rates have declined, largely due to successes in HIV, but a lot more needs to be done to defeat its “terrible twin”, tuberculosis (TB).

16 hours ago
Trans women wary of antiretroviral drug and hormone interactions

Transgender women living with HIV may be hesitant to use antiretroviral therapy (ART) or not take it as prescribed because of concerns about drug interactions with feminising hormones,

18 hours ago
Liz Highleyman
Obituary: Prudence Mabele

“She was an incredibly articulate, authentic, and real voice demonstrating the struggles and needs of many people, particularly women living with HIV and affected by gender-based violence”, Shaun Mellors said. “For many of us, she was the activist that we aimed to become.”

22 August 2017
The Lancet (free registration required)
Globally, People With HIV Are Starting Treatment Earlier

But the median CD4 count at treatment start is below 350, which means work is needed to catch up to World Health Organization guidelines.

21 August 2017
Bristol-Myers Squibb nixes 58 marketing jobs as HIV medications near patent cliff

Bristol-Myers Squibb will soon bid farewell to its exclusive lock on a pair of HIV drugs—and, as a result, 58 workers will bid farewell to their jobs.

21 August 2017
PrEP impact trial questions and answers

NHS England has announced the start of a pioneering implementation trial to provide HIV prevention drugs to people at high risk of HIV infection.

21 August 2017
NHS England
Gilead's Newer Tenofovir Patents

The company may have found a way to protect its newest HIV franchise for longer than anticipated, perhaps 10 years longer than it suggests in its 10-K (see p. 15), in both the US and EU.

15 August 2017
Seeking Alpha
Mylan launches 3 HIV generics in Canada

Mylan has launched three generics for treating HIV in Canada. Among the three launches is the company’s generic of Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate, 200 mg/300 mg), as well as generics of Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate, 600 mg/200 mg/300 mg) and Viread (tenofovir disoproxil, 300 mg).

11 August 2017
Drug Store News
In first, healthcare provider to subsidize HIV medication

The decision by Meuhedet to subsidize a generic version of the drug Truvada is set to drive a dramatic drop in prices for HIV medication. Under the new policy, Meuhedet patients were expected to pay NIS 300-500 ($83-$138) for the medication instead of the current cost of some NIS 2,100 ($580).

08 August 2017
The Times of Israel
AbbVie Mavyret Price Threatens Gilead Hepatitis Dominance

AbbVie could have charged a premium for its broader, faster cure. Its choice to go cheap will make Mavyret a huge bargain relative to Gilead's drugs for many patients. Payers will likely seize on that. The major PBMs have purposefully held off on announcing which HCV drugs they'll cover next year. Gilead will have to offer very large discounts or expect to lose market share.

07 August 2017
← First12345...623Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.